T3D Therapeutics
Business Services · North Carolina, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
68 Tw Alexander Dr, Durham, North Caroli...Phone Number
(919) 237-4897Website
www.t3dtherapeutics.comRevenue
$5.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About T3D Therapeutics
T3D Therapeutics is focused on developing innovative treatments for Alzheimer's disease and other neurodegenerative disorders, particularly Huntington's disease. Their lead product candidate, T3D-959, aims to address the underlying neuro-metabolic issues associated with Alzheimer's, such as brain starvation and neurodegeneration. The company seeks to transform the treatment landscape by potentially improving cognitive and motor functions in affected patients. Founded in 2013, T3D Therapeutics challenges traditional approaches to Alzheimer's therapy with a novel metabolic perspective.Explore more
T3D Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is T3D Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if T3D Therapeutics had a recent Job posting/layoffs
T3D Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once T3D Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if T3D Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at T3D Therapeutics
Check if T3D Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when T3D Therapeutics launches new products
Earning: See what the market has to say on T3D Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined T3D Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to T3D Therapeutics
Compare insights from companies similar to T3D Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
T3D Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
T3D Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about T3D Therapeutics.
T3D Therapeutics financials insights
Gather financial insights about T3D Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Private Equity
$660K
2018
Debt
$711K
2019
Other Financing Round
$15M
T3D Therapeutics Tech Stack
A closer look at the technologies used by T3D Therapeutics
See more technologies
T3D Therapeutics News & Media
A Novel Way to Reduce Alzheimer's Amyloid Plaque Burden, Phase 2 Clinical Trial Results of T3D-959 to be Presented by T3D Therapeutics at AAIC
New cognition/function and extensive plasma biomarker results of T3D-959 treatment from the Phase 2 PIONEER trial, in a modified intent-to treat population of mild to moderate Alzheimer's patients will be presented at the upcoming Alzheimer's Association International Conference (AAIC) in...T3D Therapeutics Announces Positive Top-Line Results from the Phase 2 PIONEER Trial of T3D-959 in Mild-To-Moderate Alzheimer's Disease
RESEARCH TRIANGLE PARK, N.C., Nov. 3, 2023 /PRNewswire/ -- T3D Therapeutics presented top-line results from its Phase 2 PIONEER study at the 16th international conference on Clinical Trials in Alzheimer's Disease (CTAD). The double-blind study compared 3 doses of T3D-959 versus placebo...T3D Therapeutics Selected to Present Topline Results from the Phase 2 PIONEER Study of T3D-959 as Late Breaking News at the 16th Clinical Trials on Alzheimer's Disease Conference (CTAD)
RESEARCH TRIANGLE PARK, N.C., Oct. 3, 2023 /PRNewswire/ -- T3D Therapeutics, Inc. ("T3D") a clinical stage drug development company engaged in the development of T3D-959, a new orally administered drug intended for the treatment of mild-to-moderate Alzheimer's disease (AD), announced...T3D Therapeutics Receives a Research Award from the Alzheimer's Association Part the Cloud-Gates Partnership Grant Program
RESEARCH TRIANGLE PARK, N.C., Aug. 27, 2020 /PRNewswire/ -- T3D Therapeutics, a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer's disease (AD), announced today that it has received a $740,000 grant from the...
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding T3D Therapeutics
Sign Up For FreeTo access detailed company insights
T3D Therapeutics is focused on developing innovative treatments for Alzheimer's disease and other neurodegenerative disorders, particularly Huntington's disease. Their lead product candidate, T3D-959, aims to address the underlying neuro-metabolic issues associated with Alzheimer's, such as brain starvation and neurodegeneration. The company seeks... Read More
